Rigetti Articulated A Credible Path To Quantum Advantage, Still A 'Buy'

Rigetti’s quantum roadmap is framed around reaching “Quantum Advantage” around 2030, but the current fidelity is cited at 91%, below the near-term target of 99.5% and the longer-term aim of 99.9%. The article highlights a tradeoff in quantum execution—pushing speed while improving accuracy—which is why fidelity is the key constraint. Overall, progress is directional but still behind stated milestones, keeping the outlook cautious.

Analysis

The market is still treating quantum as a 2030 option value story, but the investable question today is funding endurance, not eventual TAM. A platform that wins on speed while lagging badly on fidelity is at risk of becoming a perpetual science project: each incremental benchmark improvement gets harder, customer conversion stays deferred, and equity holders absorb the dilution gap between R&D spend and commercial revenue.

That creates a relative-value setup in the public quantum basket. Names with stronger balance sheets or more credible reliability paths should outperform if investors refocus on error rates and repeatability rather than raw gate speed; conversely, hardware-first pure plays with weaker fidelity progress are most exposed to multiple compression. Second-order beneficiaries are the classical compute and cloud ecosystems, because delayed quantum adoption extends hybrid-workload spending rather than replacing it.

The contrarian miss is that the most important catalyst is not a headline roadmap, but whether the company can close the fidelity gap without another capital raise. If the next 1-2 quarters show no step-up toward the 99.5% target or burn accelerates, the equity should trade more like a financing story than a breakthrough story. A credible technical inflection with unchanged cash needs is the main falsifier for a bearish view.

Key Decisions for Investors

• Short RGTI on strength into technical-update windows or earnings; 1-3 month horizon. Risk/reward is attractive if the stock re-rates on optimism but fails to show measurable fidelity progress.
• If borrow is tight, use RGTI put spreads 2-4 months out to express the view that commercialization is slipping right while dilution risk rises left; cap premium paid and avoid paying for an outright collapse.
• Pair trade: short RGTI vs long a better-capitalized quantum or adjacent compute name with less balance-sheet risk (e.g., IBM or IONQ if liquidity allows). Thesis: the market should reward reliability and funding runway more than speed demos over the next 6-12 months.
• Set a hard stop if management credibly advances toward 99.5% fidelity without incremental cash burn; that would invalidate the 'science project' thesis and likely trigger a sharp squeeze.